No profile data available.
Interpace Biosciences, Inc. (IDXG) is a healthcare company in the medical testing laboratories industry, based in Parsippany, United States, with about 102 full-time employees.
It reported revenue of $38.73 million for fiscal year 2025, down 17.5% from fiscal year 2024, and net income of $24.58 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $9.03 million, down 21.6% from a year before. Its market capitalization was $35.41 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Interpace Biosciences reported $38.73 million in revenue for fiscal year 2025, down 17.5% from $46.93 million in fiscal year 2024. In Q1 2026 revenue was $9.03 million.
$35.41 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medical testing laboratories) include Prenetics Global Limited (PRE), Lucid Diagnostics Inc. (LUCD), Precipio, Inc. (PRPO), Psychemedics Corporation (PMDI).